07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Arthrex Inc., Cytomedix deal

Cytomedix granted orthopedic device company Arthrex exclusive, worldwide development and commercialization rights to Cytomedix's Angel Concentrated Platelet Rich Plasma System for five years, with a three year renewal option. Cytomedix received an upfront payment of...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Financial News

Cytomedix financial update

Cytomedix amended its senior secured credit facility with MidCap Financial to reduce the facility to $4.5 million from $7.5 million. The parties also agreed to an accelerated payment schedule to begin on Sept. 1. Additionally,...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Clinical News

Angel Concentrated Platelet Rich Plasma System regulatory update

Cytomedix disclosed in its 4Q12 earnings that FDA granted 510(k) clearance in November for its Angel Concentrated Platelet Rich Plasma System to prepare platelet rich plasma (PRP) from blood and bone marrow aspirate. The system...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Angel Concentrated Platelet Rich Plasma System regulatory update

Cytomedix said it received CE Mark approval in the EU for its Angel Concentrated Platelet Rich Plasma System to prepare platelet rich plasma (PRP) from blood and bone marrow aspirate. The system is now approved...